Alnylam Pharmaceuticals 株価情報 (NASDAQ: ALNY)

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Large Cap

News

Movers

ALNY

CVNA

FTAI

MSTR

RDDT

RIVN

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？Rivian Automotive, Inc. (NASDAQ:RIVN)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの 合弁事業を発表したという報告書に続き、先週30.04％急騰しました。

過去1週間の大型株を特集　米国市場での存在感は

Equities

Markets

AFRM

NVDA

TSLA

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。

Nvidiaが米国の主要株価指数を牽引　

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

Price Target

Analyst Ratings

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of $(1.03)</a>.
The company reported quarterly sales of $594.2 million, up 20% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45132168/alnylam-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-recent-period-" rel="noreferrer noopener">consensus of $585.8 million</a>.
<ul>
<li>Net product revenues increased 28% and 30% at actual currency and CER, respectively, due to growth from Amvuttra driven by increased patient demand, partially offset by a decrease in Onpattro due to patient switches to Amvuttra, and an increased number patients on Givlaari.</li>
<li><a href="https://www.benzinga.com/25/03/44463008/jp-morgan-sees-convincing-multi-billion-dollar-opportunity-for-alnylam-pharmaceuticals-upgrades-stock" target="_blank" rel="noreferrer noopener">Amvuttra</a> and Onpattro sales for the first quarter reached&nbsp;$310 million&nbsp;and&nbsp;$49 million, respectively, representing 36% growth compared to Q1 2024.</li>
<li>Givlaari and Oxlumo sales reached $67 million&nbsp;and&nbsp;$42 million, respectively, representing 8% growth.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Guidance: Alnylam affirmed fiscal 2025 sales guidance of $2.70 billion-$3 billion compared to the consensus of $2.91 billion, including:
<ul>
<li>Total TTR net product revenues (Amvuttra and Onpattro) of $1.6 billion-$1.725 billion.</li>
<li>Total rare net product revenues (Givlaari and Oxlumo) of $450 million&nbsp;&#8211;&nbsp;$525 million.</li>
</ul>
On Monday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Alnylam&#8217;s vutrisiran for wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). European Commission decision is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45036384/alnylam-receives-positive-chmp-opinion-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-c" rel="noreferrer noopener">expected in June 2025</a>.
&#8220;Commercially, we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy, and we are encouraged by the launch activities discussed on the conference call,&#8221; Chardan analyst Keay Nakae writes.
Nakae maintains the Buy rating with a<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings" target="_blank" rel="noreferrer noopener"> price target of $325</a>.
William Blair analyst Myles R. Minter writes, &#8220;On the ongoing Section 232 review of potential pharmaceutical tariffs, management highlighted minimal predicted exposure given that the majority of manufacturing processes and IP are housed within the U.S.&#8221;
Minter writes, &#8220;We continue to see Amvuttra as well positioned and differentiated in the lucrative TTR-CM market and would be buyers of Alnylam stock ahead of future quarters. Despite intraday volatility in trading, in part due to investor questions over why TTR-CM launch metrics like patient or script volume numbers were not provided when they are for BridgeBio Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby, we believe management remains confident about Amvuttra&#8217;s potential and early access/reimbursement metrics provided appear favorable for a product in the infancy of a launch.&#8221;
Price Action: ALNY stock was up 1.67% at $259.39 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/05/45169853/taiwan-semiconductor-gains-on-strong-earnings-from-meta-and-microsoft-boosting-ai-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Gains On Strong Earnings From Meta And Microsoft Boosting AI Demand</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Biotech

Earnings

Guidance

Health Care

General

BBIO

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) price target from $10 to $9. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Kohl&#8217;s shares closed at $7.21 on Thursday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from $400 to $460. Needham analyst Ryan MacDonald maintained a Buy rating. Duolingo shares closed at $400.00 on Thursday. <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital raised Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $300 to $325. Chardan Capital analyst Keay Nakae maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $255.13 on Thursday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>D. Boral Capital cut the price target for GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) from $14 to $9. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. GeoVax Labs shares closed at $0.9893 on Thursday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $230 to $250. DA Davidson analyst Gil Luria maintained a Buy rating. Apple shares settled at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) price target from $52 to $10. Jefferies analyst Akash Tewari downgraded the stock from Buy to Hold. Arvinas shares closed at $7.23 on Thursday. <a href="https://www.benzinga.com/quote/ARVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $42 to $32. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Clear Secure shares closed at $24.40 on Thursday.  <a href="https://www.benzinga.com/quote/YOU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham lowered the price target for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from $52 to $40. Needham analyst Scott Berg maintained a Buy rating. Five9 shares settled at $25.08 on Thursday. <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Strategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) price target from $409 to $464. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Strategy shares closed at $381.60 on Thursday. <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png" alt="" class="wp-image-898959" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-768x454.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

AAPL

ARVN

DUOL

FIVN

GOVX

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $300 to $325.

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 11.06% on an annualized basis producing an average annual return of 19.26%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.08 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a price of $263.34 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746112529_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals Affirms FY2025 Sales Guidance of $2.70B-$3.00B vs $2.91B Est

Earnings Beats

Alnylam Pharmaceuticals Q1 Adj. EPS $(0.01) Beats $(1.03) Estimate, Sales $594.19M Beat $585.82M Estimate

AAMI

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Alnylam Receives Positive CHMP Opinion For Vutrisiran In Treatment Of ATTR Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 17.69% since its last report. The company recently reported that it has 2.99 million shares sold short, which is 3.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745254820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.52% on an annualized basis producing an average annual return of 19.0%. Currently, Alnylam Pharmaceuticals has a market capitalization of $29.89 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,352.84 today based on a price of $230.93 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744758911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and lowers the price target from $284 to $268.

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $268

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Reiteration

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

Government

GILD

REGN

VRTX

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 17.65% since its last report. The company recently reported that it has 2.54 million shares sold short, which is 2.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743785125_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 6.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Alnylam Pharmaceuticals Gaining or Losing Market Support?

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $500 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $500 Price Target

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 27 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">15</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $338.44, with a high estimate of $500.00 and a low estimate of $280.00. Witnessing a positive shift, the current average has risen by 5.09% from the previous average price target of $322.04.
<img src="https://www.benzinga.com/files/images/story/2025/1743458484_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$284.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>About Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 34.9%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -14.12%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -168.47%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.98%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 19.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $338 to $342.

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $342

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 10.98% on an annualized basis producing an average annual return of 18.93%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.33 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a price of $265.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743433215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Redburn Atlantic analyst Joshua Smith initiates coverage on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy rating and announces Price Target of $353.

Initiation

Redburn Atlantic Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $353

Press Releases

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

COEP

RPRX

SMMT

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Chardan Capital

Morgan Stanley

Needham

HC Wainwright & Co.

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの <a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener">合弁事業を発表した</a>という報告書に続き、先週30.04％急騰しました。</li>
<li>Carnival Plc（NYSE:CUK）の株は、<a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener">予想を上回る第2四半期の決算</a>を受けた株価の持続的な強さにより17.78％上昇しました。</li>
<li>FedEx Corporation（NYSE:FDX）の株は先週、予想を上回る第4四半期の財務諸表と業績予測により17.51％急騰しました。さらに、同社は「2025年度に株式2.5十億ドルを自社株買いのために買い戻す見通し」としている<a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a>と発表しました。複数のアナリストが株価予測を引き上げました。<a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a></li>
<li>多くのアナリストが「強気」のレーティングを維持し、<a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener">価格ターゲットを47ドルに維持し</a>たことを受け、RBCキャピタルがアウトパフォーム評価を再確認したことから、Samsara Inc. （NYSE:IOT）の株価は16.37％上昇しました。</li>
<li>Suzano S.A.（NYSE:SUZ）の株は、同社がInternational Paper Co.（NYSE:IP）の買収を<a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">取りやめたと発表したこと</a>を受け、12.24％上昇しました。</li>
<li>Carvana Co.（NYSE:CVNA）の株は、6月初旬のWilliam Blair株44回目の年次グロース株式投資<a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener">カンファレンスで、自社の運営計画と資本構造を更新した後、11.93％上昇しました。</a></li>
<li>FTAI Aviation Ltd.（NASDAQ:FTAI）の株は先週11.55％上昇しました。</li>
<li>Reddit, Inc.（NYSE:RDDT）の株は、同社が<a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">自動ウェブサイトスクレイピングをブロックする方針を発表したこと</a>を受け、11.08％急騰しました。</li>
<li>Mongodb Inc（NASDAQ:MDB）の株は、先週10.57％急騰しました。</li>
<li>Alnylam Pharmaceuticals, Inc.（NASDAQ:ALNY）の株は、同社がvutrisiranのHELIOS-B第3フェーズ試験のトップラインの結果を発表したことを受けて10.82％上昇しました。複数のアナリストが<a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">同社の株価予測を引き上げた</a>と発表しました。</li>
</ol>

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。
以下は、この日一日中小売トレーダーや投資家の関心を集めたトップ銘柄です。
Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidiaの株は6.68％減の118.11ドルで取引を終えました。株の日中の高値は124.46ドル、安値は118.04ドルでした。株の52週レンジは39.23ドルから140.76ドルの間です。この半導体企業はCEOのJen Huangが1億ドル以上の株式を売却した<a href="https://www.benzinga.com/markets/equities/24/06/39462808/semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60-400-whats-driv">売り勢の後</a>に、株価は訂正進入しました。
Affirm Holdings Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)
Affirmの株は12.82％上昇し、33.70ドルで取引を終了しました。株の日中の高値は34.13ドル、安値は30.77ドルでした。株の52週レンジは12.81ドルから52.48ドルの間です。ゴールドマン・サックスのアナリストWill NanceがAffirmの株式をBuy評価と42ドルの目標株価でカバーしました。
Carnival Corporation(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)
Carnivalの株は1.99％上昇し、16.39ドルで取引を終了しました。その日の株の最高値は16.5ドル、最安値は16ドルでした。この株の52週レンジは10.84ドルから19.74ドルの間です。同社は火曜日に<a href="https://www.benzinga.com/general/entertainment/24/06/39464753/carnival-stock-in-strong-bullish-trend-ahead-of-q2-earnings-why-analyst-sees-multiyear-port">四半期決算</a>を発表する予定で、ウォール街は純利益20セント/株、売上高57億ドルを予想しています。
Alnylam Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)
Alnylamの株は34.52％急騰し、222.90ドルで終了しました。株の日中の高値は231.64ドル、安値は209.23ドルでした。この株の52週レンジは141.98ドルから231.64ドルの間です。株価は同社が開発中のATTR心筋症向けのRNAi治療薬であるvutrisiranのHELIO-Bフェーズ3試験で<a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s">良好な結果を発表した後</a>に上昇しました。
Tesla Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Teslaの株はわずか0.23％減の182.58ドルで取引を終了しました。株の日中の高値は188.8ドル、安値は182.55ドルでした。株の52週レンジは138.8ドルから299.29ドルの間です。Gary Blackが、Delaware州の裁判官が「Tornetta vs. Musk」事件で<a href="https://www.benzinga.com/news/24/06/39449373/tesla-bull-gary-black-slams-delaware-chancellors-judicial-activism-in-elon-musks-56b-pay-package-cas">司法活動を行ったと批判</a>しました。この事件は、TeslaのElon Muskが保有する560億ドルの報酬パッケージを争うものであり、司法の役割や立法の対応についての広範な議論を呼びました。
株価の予想動きとビジネスニュースのトップで、ベンジンガによる本日の取引に備えよ。
このストーリーは<a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>によって生成されたもので、<a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>によって編集されました。

Comments

Alnylam Pharmaceuticals

ニュース

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

月曜日, 7 01, 2024

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル